Ipsen (OTCMKTS:IPSEY) Shares Pass Above 200 Day Moving Average – Should You Sell?

Ipsen S.A. (OTCMKTS:IPSEY)’s share price passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $29.22 and traded as high as $30.19. Ipsen shares last traded at $30.09, with a volume of 1,351 shares traded.

Analyst Upgrades and Downgrades

Separately, Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Ipsen in a research note on Wednesday, April 2nd.

Ipsen Price Performance

The stock has a 50 day simple moving average of $28.49 and a 200 day simple moving average of $29.22.

Ipsen Increases Dividend

The firm also recently announced a dividend, which will be paid on Wednesday, June 25th. Stockholders of record on Tuesday, June 10th will be paid a dividend of $0.2896 per share. The ex-dividend date is Monday, June 9th. This is a boost from Ipsen’s previous dividend of $0.23. This represents a dividend yield of 0.97%.

About Ipsen

Ipsen SA operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial.